Stephanie Parker Di Troia, PhD
About Stephanie Parker Di Troia, PhD
Stephanie Parker Di Troia, PhD, serves as a CMG Senior Analyst at the Broad Institute of MIT and Harvard, where she has worked since 2018. She has a background in genomics and biomedical sciences, with previous positions at HudsonAlpha Institute for Biotechnology and the University of California, San Francisco.
Work at Broad Institute
Stephanie Parker Di Troia has been serving as a CMG Senior Analyst at the Broad Institute of MIT and Harvard since 2018. In this role, she contributes to various genomic research initiatives, focusing on the Rare Genomes Project. Her work involves analyzing genomic data to support advancements in personalized medicine and rare disease research. The Broad Institute is known for its collaborative approach to biomedical research, and Di Troia's position reflects her expertise in genomics.
Previous Experience in Genomics
Before her tenure at the Broad Institute, Di Troia worked as a Genomics Research Associate at the HudsonAlpha Institute for Biotechnology from 2009 to 2011. During this time, she engaged in research that contributed to the understanding of genomics and its applications. Additionally, she held a position at the University of California, San Francisco, where she was involved in translational and policy research on personalized medicine from 2017 to 2018.
Education and Expertise
Di Troia earned her PhD in Biomedical Sciences from the University of California, San Francisco, completing her studies from 2011 to 2017. Her academic background includes a Bachelor of Science in Physics from The University of Alabama, where she also studied minors in Chemistry and Mathematics. This educational foundation supports her analytical skills and expertise in genomics and biomedical research.
Research Background
Stephanie Parker Di Troia has a diverse research background that includes work in genetics and neurodegeneration at The University of Alabama from 2008 to 2009. Her experience spans various aspects of genomics and personalized medicine, allowing her to contribute effectively to research projects at the Broad Institute and other institutions.